151 related articles for article (PubMed ID: 19863532)
1. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
Nakabayashi M; Oh WK; Jacobus S; Regan MM; Taplin ME; Kantoff PW; Rosenberg JE
BJU Int; 2010 May; 105(10):1392-6. PubMed ID: 19863532
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.
Lo EN; Beckett LA; Pan CX; Robles D; Suga JM; Sands JM; Lara PN
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):144-8. PubMed ID: 25667107
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
[TBL] [Abstract][Full Text] [Related]
5. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.
Sartor O; Nakabayashi M; Taplin ME; Ross RW; Kantoff PW; Balk SP; Oh WK
Clin Genitourin Cancer; 2009 Oct; 7(3):E90-2. PubMed ID: 19815488
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of low dose ketoconazole therapy for Chinese patients with castration resistant prostate cancer].
Lin GW; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Ma CG; Xiao WJ; Qin XJ
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):520-3. PubMed ID: 22490153
[TBL] [Abstract][Full Text] [Related]
7. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
8. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
Keizman D; Huang P; Carducci MA; Eisenberger MA
Prostate; 2012 Mar; 72(4):461-7. PubMed ID: 21688281
[TBL] [Abstract][Full Text] [Related]
9. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
Procopio G; Guadalupi V; Giganti MO; Mariani L; Salvioni R; Nicolai N; Capone F; Valdagni R; Bajetta E
BJU Int; 2011 Jul; 108(2):223-7. PubMed ID: 21078047
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.
Gil-Bazo I; Arévalo E; Castillo A; Zudaire ME; Carranza OE; Fusco JP; Castañón E; Collado-Gómez V; López I; Gil-Aldea I
Clin Genitourin Cancer; 2013 Jun; 11(2):78-84. PubMed ID: 23260990
[TBL] [Abstract][Full Text] [Related]
11. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
[TBL] [Abstract][Full Text] [Related]
12. Secondary hormonal manipulations in the treatment of castration refractory prostate cancer.
Agarwal N; Vogelzang NJ
BJU Int; 2011 Jul; 108(2):227-8. PubMed ID: 21410863
[No Abstract] [Full Text] [Related]
13. Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study.
Barata PC; Cooney M; Mendiratta P; Tyler A; Dreicer R; Garcia JA
Invest New Drugs; 2018 Dec; 36(6):1085-1092. PubMed ID: 30191523
[TBL] [Abstract][Full Text] [Related]
14. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
[TBL] [Abstract][Full Text] [Related]
15. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.
Gallagher DJ; Cronin AM; Milowsky MI; Morris MJ; Bhatia J; Scardino PT; Eastham JA; Offit K; Robson ME
BJU Int; 2012 Mar; 109(5):713-9. PubMed ID: 21756279
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
Agus DB; Sweeney CJ; Morris MJ; Mendelson DS; McNeel DG; Ahmann FR; Wang J; Derynck MK; Ng K; Lyons B; Allison DE; Kattan MW; Scher HI
J Clin Oncol; 2007 Feb; 25(6):675-81. PubMed ID: 17308272
[TBL] [Abstract][Full Text] [Related]
17. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
[TBL] [Abstract][Full Text] [Related]
18. Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
Peer A; Gottfried M; Sinibaldi V; Carducci MA; Eisenberger MA; Sella A; Leibowitz-Amit R; Berger R; Keizman D
Prostate; 2014 Apr; 74(4):433-40. PubMed ID: 24338986
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.
Nakano K; Ohta S; Komatsu K; Kubo T; Nukui A; Suzuki K; Kurokawa S; Kobayashi M; Morita T
BMC Urol; 2012 Feb; 12():3. PubMed ID: 22353627
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Rehman OU; Nadeem ZA; Fatima E; Akram U; Imran H; Husnain A; Nadeem A; Rasheed W
Clin Genitourin Cancer; 2024 Apr; 22(2):483-490.e5. PubMed ID: 38296679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
